Skip to main content
Premium Trial:

Request an Annual Quote

Caliper Appoints McAree CFO, Cech to Give up Presidency of HHMI, Febit Names SAB, and More

NEW YORK (GenomeWeb News) – Peter McAree has been promoted to senior VP and CFO at Caliper Life Sciences, as Thomas Higgins plans to step down from his role as the current CFO. McAree worked in financial management and accounting positions at Zymark before that company merged with Caliper in 2003. Caliper also has promoted Corporate Controller Joseph Griffith to the role of VP of finance.

PsychoGenics has named Mark Day to be senior director of cognitive neuroscience. Day formerly was involved in developing cognitive treatments for schizophrenia and Alzheimer’s disease at Wyeth Neuroscience and at GlaxoSmithKline.

Axela has appointed Dave Lemus, David Giddings, and Bill Clarke to its board of directors. Lemus is CFO at MorhphoSys and formerly was a controller and operations manager at F. Hoffman-La Roche. Giddings currently is president and CEO of Digilab, and he previously was president and COO of Boehringer Mannheim and VP and GM of Kodak Clinical Diagnostics. Clarke is CEO at Cellectar, and he also has served as executive VP, CTO, and CMO at GE Healthcare and he was an executive at Amersham and at Glaxo Wellcome UK.

Agendia has named Richard Bender as VP and chief medical officer.
Bender was medical director in the oncology division of Quest Diagnostics, and he was involved in clinical oncology at Kaiser Permanente. Bender also was on the executive board of San Diego’s Hospice and the American Cancer Society and he was an instructor at the UCLA School of Medicine.

Thomas Cech will give up his presidency of the Howard Hughes Medical Institute, a post he has held since the beginning of 2000, in the spring of 2009, HHMI said this week.
Cech has been on faculty at the University of Colorado since 1978 and was named an HHMI investigator in 1988. Cech was part of a research group that in 1982 discovered self-splicing RNA, and during his era as president he has continued to maintain his own research, lately studying regulation of telomerase.
“Leading HHMI is truly one of the great jobs in American science — if not the world — but I recently decided that the time had come to consider a transition for HHMI and myself,” Cech told HHMI’s staff, according to a statement. “I'm ready to return to the adventure of my own research and my own teaching,” he added.

ExonHit Therapeutics said this week that Matthew Pando and John Jaskowiak will join the company’s management board, and Philippe Rousseau will become president of that board until the company appoints a new CEO. Rousseau has been CFO at ExonHit since 2002 and has been a member of its management board since 2004.
Jaskowiak started with the company in 2006, and was recently appointed head of Molecular Diagnostics and Genomic Services. Pando came to the company in 2002, and recently was named head of its Therapeutics Unit.

Bernhard Iseli will resign from his post as a member of Tecan’s executive committee and from his role as head of the company’s sample management unit. Iseli came to Tecan through its acquisition of REMP in 2005.

Febit said this week that it has formed its scientific advisory board. The SAB consists of:
Mark Chee, who is to be chairman and was formerly at Affymetrix and was co-founder of Illumina; Karoly Nikolich, who was executive director of the Neuroscience Institute of Stanford; David Lockhart, who is CSO of Amicus Therapeutics, and formerly of Affymetrix; Mostafa Ronaghi, a researcher at Stanford who is one of the inventors of pyrosequencing; and Jeffrey Trent, who is president and scientific director of the Translational Genomics Research Institute.

Pacific Biomarkers has named Tara Hennen, a member of the company’s science and technology group, to be manager of its Biomarker Lab Services business.

Promoted? Changing jobs? GenomeWeb wants to know. E-mail [email protected] to appear in PEOPLE, a weekly roundup of industry comings and goings.

The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.